Vor Bio: Valuation, Funding & Investors
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide.
Leadership & Board
- Current Number of Employees
- 132
- Current LinkedIn Followers
- 20,586
Latest Estimated Valuation
- Total Amount Raised
- $150M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $150M
- Latest Funding Round
- Investment
Employee Trend
Vor Bio had 132 employees as of November 2, 2026. The number of employees increased by 0 (0.00%) week-over-week.
132Latest Employee Count
0(0.00%)Week-Over-Week Change
Social Trend
Vor Bio had 20,586 followers as of November 2, 2026. The number of followers increased by 34 (0.17%) week-over-week.
20,586Latest Followers Count
34(0.17%)Week-Over-Week Change
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Dec 15, 2025 | Investment | $150.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| RA Capital Management | Investment |
| Forbion | Investment |
| Frazier Life Sciences | Investment |
| Logos Capital | Investment |
| Venrock Healthcare Capital Partners | Investment |
| Caligan Partners | Investment |
Similar Companies
A snapshot of private companies similar to Vor Bio, helping you discover and navigate related company profiles.
Related News and Analysis
